ME-401 for Chronic Lymphocytic Leukemia

"According to official documentation from clinicaltrials.gov, this particular trial is no longer seeking patients as of August 17th 2022. Although the study began recruiting on October 1st 2016, there are currently 2362 other medical trials actively searching for volunteers in lieu of this one."

"This clinical trial's primary aim is to assess the safety and tolerance of ME-401 when combined with zanubrutinib, evaluated over 56 days. Secondary objectives include examining the peak plasma concentrations (Cmax) of ME-401 alone, assessing any treatment related adverse events via CTCAE v4.0, as well as calculating the Area Under the Concentration time curve (AUC)."

"At the moment, this clinical study is not seeking new candidates. The trial was posted on October 1st 2016 and last revised August 17th 2022. For those looking for alternative experiments to join, 1936 studies recruiting lymphoma patients using b-cells are available, as well as 426 trials actively enrolling participants in ME-401 research."

"In 1993, ME-401 had its debut at the National Institutes of Health Clinical Centre. Since then 823 trials have been concluded and 426 are currently underway. Many of these studies take place in Oklahoma City, OK."

"At present, 22 medical facilities are enrolling patients for this research. The list of locations includes Oklahoma City, Cleveland and Nashville, plus 19 other sites across the nation; make sure to select a site close by in order to reduce travelling expenses if you participate."

"The safety of ME-401 is rated 1 out of 3 due to the lack of data in regards to its efficacy and limited evidence regarding its security."

"ME-401 is a promising treatment for conditions such as relapsed marginal zone lymphoma, diffuse large b-cell lymphoma (dlbcl), and other forms of B cell lymphomas or polyangiitis."